Gastroenterology

Following is a digest of pharmacogenomics journal articles pertaining to gastroenterology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & LinkTypeMonthSNP•its Study Summary
Lee MN et al. Impact of genetic polymorphisms on 6-thioguanine nucleotide levels and toxicity in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 2015;21:2897-908.Observational2015-12
Buendía JA et al. Combinational effect of CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics in liver transplant patients. Exp Clin Transplant. 2015;13:441-8.Prospective Cohort2015-10
Coenen MJ et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149:907-17.Randomized Controlled Trial2015-10
Argudo A et al. Liver transplant patient carriers of polymorphism CYP3A5*1 donors may need more doses of tacrolimus from the first month after transplantation. Transplant Proc. 2015;47:2388-92.Retrospective Cohort2015-10
Coenen MJ et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterol. 2015;149:907-17.Randomized Controlled Trial2015-10
Sanderson JD. TPMT testing before starting azathioprine or mercaptopurine:
surely just do it? Gastroenterology.
2015;149:850-3.
Opinion2015-10
Shuldiner SR et al. PharmGKB summary: peginterferon-? pathway. Pharmacogenet Genom. 2015;25:465-74.PharmGKB Summary2015-09
Acosta A et al. Pharmacogenetics in irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2015;11:1187-91.Editorial2015-08
Roberts RL et al. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891–903.Review2015-07
van der Schaft J et al. Increased liver enzyme levels during azathioprine treatment; beware of concomitant use of proton pump inhibitors. Br J Dermatol. 2015 Jul 3 [Epub ahead of print];Letter2015-07
Roberts RL et al. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891-903.Review2015-07
Kakuta Y et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2015 Jun 16 [Epub ahead of print].Prospective Cohort2015-06
Coenen MJH et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015 Jun 11 [Epub ahead of print].Prospective Cohort2015-06
Yang TH et al. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract. 2015;69 Suppl 183:53–62.Cohort2015-05
Bouziana SD et al. Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther. 2015;6:17–21.Review2015-05
Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury (DILI): current role in clinical practice. Liver Int. 2015 Mar 24 [Epub ahead of print].Review2015-03
Liu Y-P et al. Association between thiopurine s-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS ONE. 2015;10:e0121745.Meta-Analysis2015-03
Anonymous. Thiopurine-induced leucopenia and hair loss were inevitable in Japanese IBD patients homozygous for NUDT15 R139C: a case series. J Crohns Colitis. 2015;9 Suppl 1:S428.Case Series2015-02
Jainan W et al. Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pac J Cancer Prev. 2014;15:10957–60.Prospective cohort2014-12
Katsanos KH et al. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics. 2014;15:2049–62.Review2014-12
Shiotani A et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. . J Gastroenterol Hepatol. 2014;29 Suppl 4:47–52.Retrospective cohort2014-12
Dietrich CG et al. Effect of drug transporter pharmacogenetics on cholestasis. Expert Opin Drug Metab Toxicol. 2014;10:1533–51.Review2014-11
Kuo C-H et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20:16029–36.Review2014-11
Kuo C-H et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20:16029–36.Review2014-11
Serdjebi C et al. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift? Pharmacogenet Genomics. 2014;24:527–9.Case Report2014-11
Román M et al. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. Pharmacogenomics. 2014;15:1893–1901.Pharmacokinetic2014-11
Chen YK et al. Personalized tacrolimus dose requirement by CYP3A5 but Not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS ONE. 2014;9:e109464.Retrospective Cohort2014-10
Kim HY et al. Safe azathioprine treatment in a pediatric ulcerative colitis patient with TPMT*16 by thiopurine metabolite monitoring. Clin Chim Acta. 2014;437:101–2.Case Report2014-10
Hariharan S et al. Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means. J Clin Pharmacol. 2014;54:884-8. Commentary2014-08 
Buendia J et al. Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients: A Meta-Analysis. Ther Drug Monit. 2014;36:442-7. Meta-analysis2014-08 
Serdjebi C et al. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: A deadly gift? Pharmacogenet Genomics. 2014; [Epub ahead of print]. Case report2014-07 
Indolfi G et al. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: From adults to children. World J Gastroenterol. 2014;20:9245-52. Review2014-07 
Depta J, et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2014; [Epub ahead of print]. Retrospective analysis2014-07 
Kim H et al. Safe azathioprine treatment in a pediatric ulcerative colitis patient with TPMT*16 by thiopurine metabolite monitoring. Clin Chim Acta. 2014;437C:101-2. Case report2014-07 
Festen EAM et al. How will insights from genetics translate to clinical practice in inflammatory bowel disease? Best Pract Res Clin Gastroenterol. 2014 May 14. [Epub ahead of print] Review2014-06 
Irving PM. Can we get more from our current treatments? Best Pract Res Clin Gastroenterol. 2014 May 5. [Epub ahead of print].Review2014-06 
Beswick L et al. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2014;8:383–92.Review2014-05
Gupta A et al. Novel use of pharmacogenetic testing in the identification of CYP2C9 polymorphisms related to NSAID-induced gastropathy. Pain Med. 2015 Jan 13 [Epub ahead of print].Case report2014-01